Allergan to Present Data from its Eye Care Portfolio at the AAO Annual Meeting, Including New Vuity Analysis

Allergan, an AbbVie company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of Vuity (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the first and only eye drop to treat presbyopia; additional analyses on Durysta (bimatoprost intracameral implant); and three real-world data studies on the glaucoma patient journey at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting, November 12-15.

"The importance of improving visual function cannot be overstated, especially in the context of conditions such as presbyopia, which can have a significant effect on daily activities," Michael R. Robinson, MD, vice president, global therapeutic area head, eye care, AbbVie, said in a company news release. "The research we will present at the AAO 2021 Annual Meeting reflects our ongoing commitment to innovation that can change how patients manage their conditions."

Roughly 128 million people, nearly half of the U.S. adult population, experience age-related blurry near vision or presbyopia, a common and progressive eye condition that reduces the eye's ability to focus on near objects and usually impacts people after age 40. 

Vuity is the first and only FDA-approved eye drop to treat presbyopia, commonly known as age-related blurry near vision, in adults. Vuity is a daily, prescription eye drop that improves near and intermediate vision without impacting distance vision. Specifically designed for presbyopia, Vuity is an optimized formulation of pilocarpine, an established eye care therapeutic, delivered with pHast technology. The proprietary pHast technology allows Vuity to rapidly adjust to the physiologic pH of the tear film. Vuity uses the eye's own ability to reduce pupil size, improving near vision without affecting distance vision.

Researchers will also present data from an ongoing 24-month extension study of the phase 3 ARTEMIS study assessing the efficacy and duration of Durysta. Durysta was approved by the FDA in March 2020 to reduce eye pressure in patients with open angle glaucoma (OAG) or high eye pressure (ocular hypertension, or OHT). Allergan has continued to further research Durysta to identify best use and practices in the clinical setting.

A complete listing of the Allergan AAO 2021 Annual Meeting abstracts can be viewed at https://registration.experientevent.com/showaao211/flow/Attendee#!/registrant//ShowItems/.

Details about Allergan's presentations are as follows: